More specifically, we found that galectin levels in plasma and expression in both cancer and peritumoral stromal cells can potentially be used to predict 5-year DFS, chemotherapy response and 5-year OS in HGSC patients and to potentiate the predictive value of CA125. This evidence concerns the gene MUC16 and cancer.